Role of iron in neurodegenerative disorders

Topics in Magnetic Resonance Imaging

Volumn 17, Issue 1, 2006, Pages 5-17

  Berg, Daniela ^a   Youdim, Moussa B H ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Brain; Iron; MRI

Indexed keywords

IRON; BIOLOGICAL MARKER;

ACERULOPLASMINEMIA; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BASAL GANGLION; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; IRON BLOOD LEVEL; LEWY BODY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SIDEROBLASTIC ANEMIA; BRAIN; IRON METABOLISM DISORDER; METABOLISM; METHODOLOGY; PATHOLOGY; REVIEW;

BIOLOGICAL MARKERS; BRAIN; HUMANS; IRON; IRON METABOLISM DISORDERS; MAGNETIC RESONANCE IMAGING; NEURODEGENERATIVE DISEASES;

EID: 34247564692     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rmr.0000245461.90406.ad     Document Type: Article

References (252)

1. Youdim MB, Ben-Shachar D, Riederer P. Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol. 1991;31(suppl 1):34-40.
2. Connor JR, Benkovic SA. Iron regulation in the brain: histochemical, biochemical, and molecular considerations. Ann Neurol. 1992;32(suppl):S51-S61.
3. Berg D, Becker G, Riederer P, et al. Iron in neurodegenerative disorders. Neurotox Res. 2002;4:637-653.
4. Riederer P, Youdim MBH, eds. Iron in Central Nervous System Disorders. Vienna, Austria: Springer; 1993.
5. Gerlach M, Ben-Shachar D, Riederer P, et al. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem. 1994;63:793-807.
6. Halliwell B, Gutteridge JM. Free Redicals in Biology and Medicine. New York, NY: Oxford University Press; 2003.
7. Burdo JR, Connor JR. Brain iron uptake and homeostatic mechanisms: an overview. Biometals. 2003;16:63-75.
8. Zecca L, Stroppolo A, Gatti A, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A. 2004;101:9843-9848.
9. Hayflick SJ. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr. 2003;15:572-577.
10. Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden-Spatz syndrome. Arch Neurol. 1974;30:70-83.
11. Swaiman KF. Hallervorden-Spatz syndrome and brain iron metabolism. Arch Neurol. 1991;48:1285-1293.
12. Swaiman KF. Hallervorden-Spatz syndrome. Pediatr Neurol. 2001;25:102-108.
13. Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004;19:36-42.
14. Savoiardo M, Halliday WC, Nardocci N, et al. Hallervorden-Spatz disease: MR and pathologic findings. AJNR Am J Neuroradiol. 1993;14:155-162.
15. Swaiman KF, Smith SA, Trock GL, et al. Sea-blue histiocytes, lymphocytic cytosomes, movement disorder and 59Fe-uptake in basal ganglia: Hallervorden-Spatz disease or ceroid storage disease with abnormal isotope scan? Neurology. 1983;33:301-305.
16. Zupanc ML, Chun RW, Gilbert-Barness EF. Osmiophilic deposits in cytosomes in Hallervorden-Spatz syndrome. Pediatr Neurol. 1990;6:349-352.
17. Taylor TD, Litt M, Kramer P, et al. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet. 1996;14:479-481.
18. Galvin JE, Giasson B, Hurtig HI, et al. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol. 2000;157:361-368.
19. Neumann M, Adler S, Schluter O, et al. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol (Berl). 2000;100:568-574.
20. Ostergaard JR, Christensen T, Hansen KN. In vivo diagnosis of Hallervorden-Spatz disease. Dev Med Child Neurol. 1995;37:827-833.
21. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol. 2001;25:148-155.
22. Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet. 2001;28:345-349.
23. Calder RB, Williams RS, Ramaswamy G, et al. Cloning and characterization of a eukaryotic pantothenate kinase gene (panK) from Aspergillus nidulans. J Biol Chem. 1999;274:2014-2020.
24. Hortnagel K, Prokisch H, Meitinger T. An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. Hum Mol Genet. 2003;12:321-327.
25. Kotzbauer PT, Truax AC, Trojanowski JQ, et al. Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci. 2005;25:689-698.
26. Hartig MB, Hortnagel K, Garavaglia B, et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol. 2006;59:248-256.
27. Klopstock T, Elstner M, Lucking CB, et al. Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease. Neurosci Lett. 2005;379:195-198.
28. Arawaka S, Saito Y, Murayama S, et al. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology. 1998;51:887-889.
29. Theil EC. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu Rev Biochem. 1987;56:289-315.
30. Rouault TA. Iron on the brain. Nat Genet. 2001;28:299-300.
31. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996;1275:161-203.
32. Mancuso M, Davidzon G, Kurlan RM, et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol. 2005;64:280-294.
33. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet. 2001;28:350-354.
34. Chinnery PF, Curtis AR, Fey C, et al. Neuroferritinopathy in a French family with late onset dominant dystonia. J Med Genet. 2003;40:e69.
35. Wills AJ, Sawle GV, Guilbert PR, et al. Palatal tremor and cognitive decline in neuroferritinopathy. J Neurol Neurosurg Psychiatry. 2002;73:91-92.
36. Maciel P, Cruz VT, Constante M, et al. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology. 2005;65:603-605.
37. Vidal R, Delisle MB, Rascol O, et al. Hereditary ferritinopathy. J Neurol Sci. 2003;207:110-111.
38. Vidal R, Ghetti B, Takao M, et al. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol. 2004;63:363-380.
39. Levi S, Cozzi A, Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with l-ferritin mutation. Best Pract Res Clin Haematol. 2005;18:265-276.
40. Ponka P. Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann N Y Acad Sci. 2004;1012:267-281.
41. Vidal R, Delisle MB, Ghetti B. Neurodegeneration caused by proteins with an aberrant carboxyl-terminus. J Neuropathol Exp Neurol. 2004;63:787-800.
42. Klomp LW, Gitlin JD. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet. 1996;5:1989-1996.
43. Okamoto N, Wada S, Oga T, et al. Hereditary ceruloplasmin deficiency with hemosiderosis. Hum Genet. 1996;97:755-758.
44. Kohno S, Miyajima H, Takahashi Y, et al. Aceruloplasminemia with a novel mutation associated with parkinsonism. Neurogenetics. 2000;2:237-238.
45. Ke Y, Ming Qian Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2003;2:246-253.
46. Grisoli M, Piperno A, Chiapparini L, et al. MR imaging of cerebral cortical involvement in aceruloplasminemia. AJNR Am J Neuroradiol. 2005;26:657-661.
47. Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals. 2003;16:205-213.
48. Kono S, Miyajima H. Molecular and pathological basis of aceruloplasminemia. Biol Res. 2006;39:15-23.
49. Harris ZL, Durley AP, Man TK, et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci U S A. 1999;96:10812-10817.
50. Reilly CA, Aust SD. Stimulation of the ferroxidase activity of ceruloplasmin during iron loading into ferritin. Arch Biochem Biophys. 1997;347:242-248.
51. Mukhopadhyay CK, Attieh ZK, Fox PL. Role of ceruloplasmin in cellular iron uptake. Science. 1998;279:714-717.
52. Attieh ZK, Mukhopadhyay CK, Seshadri V, et al. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem. 1999;274:1116-1123.
53. Qian ZM, Ke Y. Rethinking the role of ceruloplasmin in brain iron metabolism. Brain Res Brain Res Rev. 2001;35:287-294.
54. Yoshida K, Kaneko K, Miyajima H, et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci. 2000;175:91-95.
55. Xu X, Pin S, Gathinji M, et al. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Ann N Y Acad Sci. 2004;1012:299-305.
56. Miyajima H, Nishimura Y, Mizoguchi K, et al. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology. 1987;37:761-767.
57. Bost M, Berkaw M, McBride OW, et al. Restriction polymorphisms of the ceruloplasmin gene on chromosome 3. Hum Genet. 1995;96:239-240.
58. Daimon M, Morita Y, Yamatani K, et al. Dinucleotide repeat polymorphism in the human ceruloplasmin gene. Hum Genet. 1995;96:736.
59. Hellman NE, Kono S, Miyajima H, et al. Biochemical analysis of a missense mutation in aceruloplasminemia. J Biol Chem. 2002;277:1375-1380.
60. Loreal O, Turlin B, Pigeon C, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol. 2002;36:851-856.
61. Hochstrasser H, Bauer P, Walter U, et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology. 2004;63:1912-1917.
62. Miyajima H, Kono S, Takahashi Y, et al. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology. 2001;57:2205-2210.
63. Gotz ME, Double K, Gerlach M, et al. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci. 2004;1012:193-208.
64. Atasoy HT, Nuyan O, Tunc T, et al. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol India. 2004;52:332-337.
65. Bartzokis G, Cummings JL, Markham CH, et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging. 1999;17:213-222.
66. Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. AJNR Am J Neuroradiol. 2000;21:697-701.
67. Mondino F, Filippi P, Magliola U, et al. Magnetic resonance relaxometry in Parkinson's disease. Neurol Sci. 2002;23(suppl 2):S87-S88.
68. Becker G, Seufert J, Bogdahn U, et al. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology. 1995;45:182-184.
69. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol. 2001;248:684-689.
70. Walter U, Wittstock M, Benecke R, et al. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm. 2002;109:191-196.
71. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol. 2002;59:999-1005.
72. Double KL, Maywald M, Schmittel M, et al. In vitro studies of ferritin iron release and neurotoxicity. J Neurochem. 1998;70:2492-2499.
73. Lin M, Rippe RA, Niemela O, et al. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Physiol. 1997;272:G1355-G1364.
74. Youdim MB, Grunblatt E, Mandel S. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann N Y Acad Sci. 1999;890:7-25.
75. Shoham S, Youdim MB. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol (Noisy-le-grand). 2000;46:743-760.
76. Galazka-Friedman J, Friedman A. Controversies about iron in parkinsonian and control substantia nigra. Acta Neurobiol Exp (Wars). 1997;57:217-225.
77. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm. 1988;74:199-205.
78. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 1989;52:515-520.
79. Kidd PM. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev. 2000;5:502-529.
80. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003;53(suppl 3):S26-S36. discussion S36-S38.
81. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem. 1989;52:381-389.
82. Pratico D. In vivo measurement of the redox state. Lipids. 2001;36(suppl):S45-S47.
83. Montine KS, Quinn JF, Zhang J, et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids. 2004;128:117-124.
84. Stadtman ER. Protein oxidation in aging and age-related diseases. Ann N Y Acad Sci. 2001;928:22-38.
85. Goetz ME, Gerlach M. Formation of radicals. In: Herdegen T, Delgado-Garcia J, eds. Brain Damage and Repair. London, UK: Kluwer academic publishers; 2004:135-164.
86. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 2000;21:361-370.
87. Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson's disease. Neurology. 1987;37:728.
88. Alam ZI, Jenner A, Daniel SE, et al. A damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem. 1997;69:1196-1203.
89. Poon HF, Calabrese V, Scapagnini G, et al. Free radicals and brain aging. Clin Geriatr Med. 2004;20:329-359.
90. Hashimoto M, Hsu LJ, Sisk A, et al. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 1998;799:301-306.
91. Munch G, Luth HJ, Wong A, et al. Crosslinking of alpha-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J Chem Neuroanat. 2000;20:253-257.
92. Golts N, Snyder H, Frasier M, et al. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem. 2002;277:16116-16123.
93. Schipper HM, Liberman A, Stopa EG. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol. 1998;150:60-68.
94. Hochstrasser H, Tomiuk J, Walter U, et al. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J. 2005;19:1851-1853.
95. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302:819-822.
96. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun. 1989;163:1450-1455.
97. Reichmann H. RP: Biochemical analyses of respiratory chain enzymes in different brain regions of patients with Parkinson's disease. BMFT Symposium "Morbus Parkinson und andere Basalganglienerkrankungen," Bad Kissingen, 1989. Abstract p 44.
98. Liu B, Gao HM, Wang JY, et al. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci. 2002;962:318-331.
99. Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem. 2002;80:780-787.
100. Shamoto-Nagai M, Maruyama W, Kato Y, et al. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res. 2003;74:589-597.
101. Reichmann H, Janetzky B. Mitochondrial dysfunction - a pathogenetic factor in Parkinson's disease. J Neurol. 2000;247(suppl 2):II63-II68.
102. Gu M, Cooper JM, Taanman JW, et al. A transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol. 1998;44:177-186.
103. Carreras MC, Franco MC, Peralta JG, et al. Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Mol Aspects Med. 2004;25:125-139.
104. Naoi M, Maruyama W, Akao Y, et al. Apoptosis induced by an endogenous neurotoxin. N-methyl(R)salsolinol, in dopamine neurons. Toxicology. 2000;153:123-141.
105. Naoi M, Maruyama W, Akao Y, et al. Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R) salsolinol, and neuroprotection by propargylamines. J Neural Transm. 2002;109:607-621.
106. Dexter DT, Carayon A, Vidailhet M, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem. 1990;55:16-20.
107. Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord. 2005;20:1278-1285.
108. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology. 1999;20:239-247.
109. Logroscino G, Marder K, Graziano J, et al. Dietary iron, animal fats, and risk of Parkinson's disease. Mov Disord. 1998;13(suppl 1):13-16.
110. Johnson CC, Gorell JM, Rybicki BA, et al. Adult nutrient intake as a risk factor for Parkinson's disease. Int J Epidemiol. 1999;28:1102-1109.
111. Powers KM, Smith-Weller T, Franklin GM, et al. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003;60:1761-1766.
112. Shoham S, Youdim MB. Nutritional iron deprivation attenuates kainate-induced neurotoxicity in rats: implications for involvement of iron in neurodegeneration. Ann N Y Acad Sci. 2004;1012:94-114.
113. Levenson CW, Cutler RG, Ladenheim B, et al. Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp Neurol. 2004;190:506-514.
114. Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57:176-179.
115. Castelnau PA, Garrett RS, Palinski W, et al. Abnormal iron deposition associated with lipid peroxidation in transgenic mice expressing interleukin-6 in the brain. J Neuropathol Exp Neurol. 1998;57:268-282.
116. Berg D, Grote C, Rausch WD, et al. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol. 1999;25:901-904.
117. Borie C, Gasparini F, Verpillat P, et al. Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol. 2002;249:801-804.
118. Kennard ML, Feldman H, Yamada T, et al. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med. 1996;2:1230-1235.
119. Gassen M, Youdim MB. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol. 1997;80:159-166.
120. Nishikawa K, Li H, Kawamura R, et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun. 2003;304:176-183.
121. Choi J, Levey AI, Weintraub ST, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem. 2004;279:13256-13264.
122. Chung KK, Thomas B, Li X, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science. 2004;304:1328-1331.
123. Yao D, Gu Z, Nakamura T, et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A. 2004;101:10810-10814.
124. Lipton SA, Nakamura T, Yao D, et al. Comment on "S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function". Science. 2005;308:1870.
125. Lim KL, Dawson VL, Dawson TM. The genetics of Parkinson's disease. Curr Neurol Neurosci Rep. 2002;2:439-446.
126. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 2003;40:427-446.
127. Zhou W, Zhu M, Wilson MA, et al. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol. 2006;356:1036-1048.
128. Shendelman S, Jonason A, Martinat C, et al. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2004;2:e362.
129. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290:985-989.
130. 2. J Neurochem. 2003;84:1128-1142.
131. Krishnan S, Chi EY, Wood SJ, et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry. 2003;42:829-837.
132. Castellani RJ, Perry G, Siedlak SL, et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett. 2002;319:25-28.
133. Double KL, Jellinger K, Youdim MBH, et al. Iron, neuromelanin, and a-synuclein in the neuropathogenesis of Parkinson's disease. In: Zatta P, ed. Metal Ions and Neurodegenerative Disorders. New York, NY: World Scientific; 2003:343-364.
134. Walter U, Dressler D, Wolters A, et al. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology. 2004;63:504-509.
135. Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol. 2004;3:93-103.
136. Wenning GK, Tison F, Elliott L, et al. Olivopontocerebellar pathology in multiple system atrophy. Mov Disord. 1996;11:157-162.
137. Wenning GK, Ben-Shlomo Y, Magalhaes M, et al. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1995;58:160-166.
138. Sung JH, Mastri AR, Segal E. Pathology of Shy-Drager syndrome. J Neuropathol Exp Neurol. 1979;38:353-368.
139. Benarroch EE, Smithson IL, Low PA, et al. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann Neurol. 1998;43:156-163.
140. Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol. 1960;2:511-527.
141. Gai WP, Power JH, Blumbergs PC, et al. Multiple-system atrophy: a new alpha-synuclein disease? Lancet. 1998;352:547-548.
142. Duda JE, Giasson BI, Chen Q, et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol. 2000;157:1439-1445.
143. Dexter DT, Jenner P, Schapira AH, et al. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol. 1992(32(suppl)):S94-S100.
144. Martin WR, Roberts TE, Ye FQ, et al. Increased basal ganglia iron in striatonigral degeneration: in vivo estimation with magnetic resonance. Can J Neurol Sci. 1998;25:44-47.
145. Dickson DW, Lin W, Liu WK, et al. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 1999;9:721-732.
146. Vymazal J, Righini A, Brooks RA, et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology. 1999;211:489-495.
147. Savoiardo M. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci. 2003;24(suppl 1):S35-S37.
148. Golbe LI. Progressive supranuclear palsy. In: Beal MF, Lang AE, Ludolph A, eds. Neurodegenerative Diseases. Cambridge, MA: Cambridge University Press; 2005:663-681.
149. Stern MB, Braffman BH, Skolnick BE, et al. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology. 1989;39:1524-1526.
150. Savoiardo M, Girotti F, Strada L, et al. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm Suppl. 1994;42:93-110.
151. Perez M, Valpuesta JM, de Garcini EM, et al. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. Am J Pathol. 1998;152:1531-1539.
152. Troncoso JC, Costello A, Watson AL Jr, et al. In vitro polymerization of oxidized tau into filaments. Brain Res. 1993;613:313-316.
153. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54(suppl 5):S15-S19.
154. Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61:935-946.
155. Mizuno Y, Ozeki M, Iwata H, et al. A case of clinically and neuropathologically atypical corticobasal degeneration with widespread iron deposition. Acta Neuropathol (Berl). 2002;103:288-294.
156. Sastry S, Arendash GW. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex. Neuroscience. 1995;67:649-666.
157. Telenius H, Kremer HP, Theilmann J, et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet. 1993;2:1535-1540.
158. Rutledge JN, Hilal SK, Silver AJ, et al. Study of movement disorders and brain iron by MR. AJR Am J Roentgenol. 1987;149:365-379.
159. Chen JC, Hardy PA, Kucharczyk W, et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol. 1993;14:275-281.
160. Bartzokis G, Cummings J, Perlman S, et al. Increased basal ganglia iron levels in Huntington disease. Arch Neurol. 1999;56:569-574.
161. Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. Cell Mol Biol (Noisy-le-grand). 2000;46:821-833.
162. Hilditch-Maguire P, Trettel F, Passani LA, et al. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet. 2000;9:2789-2797.
163. Bonilla E, Estevez J, Suarez H, et al. Serum ferritin deficiency in Huntington's disease patients. Neurosci Lett. 1991;129:22-24.
164. Loeffler DA, Sima AA, LeWitt PA. Ceruloplasmin immunoreactivity in neurodegenerative disorders. Free Radic Res. 2001;35:111-118.
165. De Michele G, Di Salle F, Filla A, et al. Magnetic resonance imaging in "typical" and "late onset" Friedreich's disease and early onset cerebellar ataxia with retained tendon reflexes. Ital J Neurol Sci. 1995;16:303-308.
166. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet. 1997;6:1771-1780.
167. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med. 1996;335:1169-1175.
168. Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 1997;276:1709-1712.
169. Radisky DC, Babcock MC, Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem. 1999;274:4497-4499.
170. Becker E, Richardson DR. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int J Biochem Cell Biol. 2001;33:1-10.
171. Foury F. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett. 1999;456:281-284.
172. Lutz T, Westermann B, Neupert W, et al. The mitochondrial proteins Ssq1 and Jac1 are required for the assembly of iron sulfur clusters in mitochondria. J Mol Biol. 2001;307:815-825.
173. Muhlenhoff U, Lill R. Biogenesis of iron-sulfur proteins in eukaryotes: a novel task of mitochondria that is inherited from bacteria. Biochim Biophys Acta. 2000;1459:370-382.
174. Sturm B, Bistrich U, Schranzhofer M, et al. Friedreich's ataxia, no changes in mitochondrial labile iron in human lymphoblasts and fibroblasts: a decrease in antioxidative capacity? J Biol Chem. 2005;280:6701-6708.
175. Gerber J, Muhlenhoff U, Lill R. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep. 2003;4:906-911.
176. Lobmayr L, Brooks DG, Wilson RB. Increased IRP1 activity in Friedreich ataxia. Gene. 2005;354:157-161.
177. Gakh O, Park S, Liu G, et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet. 2006;15:467-479.
178. Bradley JL, Homayoun S, Hart PE, et al. Role of oxidative damage in Friedreich's ataxia. Neurochem Res. 2004;29:561-567.
179. Emond M, Lepage G, Vanasse M, et al. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology. 2000;55:1752-1753.
180. Seznec H, Simon D, Bouton C, et al. Friedreich ataxia: the oxidative stress paradox. Hum Mol Genet. 2005;14:463-474.
181. Waldvogel D, van Gelderen P, Hallett M. Increased iron in the dentate nucleus of patients with Friedreich's ataxia. Ann Neurol. 1999;46:123-125.
182. Bradley JL, Blake JC, Chamberlain S, et al. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet. 2000;9:275-282.
183. Lamarche JB, Cote M, Lemieux B. The cardiomyopathy of Friedreich's ataxia morphological observations in 3 cases. Can J Neurol Sci. 1980;7:389-396.
184. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17:215-217.
185. Lodi R, Taylor DJ, Schapira AH. Mitochondrial dysfunction in Friedreich's ataxia. Biol Signals Recept. 2001;10:263-270.
186. Pagon RA, Bird TD, Detter JC, et al. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet. 1985;22:267-273.
187. Hellier KD, Hatchwell E, Duncombe AS, et al. X-linked sideroblastic anaemia with ataxia: another mitochondrial disease? J Neurol Neurosurg Psychiatry. 2001;70:65-69.
188. Csere P, Lill R, Kispal G. Identification of a human mitochondrial ABC transporter, the functional orthologue of yeast Atm1p. FEBS Lett. 1998;441:266-270.
189. Shimada Y, Okuno S, Kawai A, et al. Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia. J Hum Genet. 1998;43:115-122.
190. Allikmets R, Raskind WH, Hutchinson A, et al. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet. 1999;8:743-749.
191. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67-113.
192. Dean M, Allikmets R. Evolution of ATP-binding cassette transporter genes. Curr Opin Genet Dev. 1995;5:779-785.
193. Bekri S, Kispal G, Lange H, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood. 2000;96:3256-3264.
194. Kispal G, Csere P, Prohl C, et al. The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins. EMBO J. 1999;18:3981-3989.
195. Pondarre C, Antiochos BB, Campagna DR, et al. The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis. Hum Mol Genet. 2006;15:953-964.
196. Kasarskis EJ, Tandon L, Lovell MA, et al. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J Neurol Sci. 1995;130:203-208.
197. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta. 1998;1366:211-223.
198. Cluskey S, Ramsden DB. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol Pathol. 2001;54:386-392.
199. Oeda T, Shimohama S, Kitagawa N, et al. Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in
200. Olsen MK, Roberds SL, Ellerbrock BR, et al. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol. 2001;50:730-740.
201. Carri MT, Ferri A, Cozzolino M, et al. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull. 2003;61:365-374.
202. Oba H, Araki T, Ohtomo K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology. 1993;189:843-846.
203. Yasui M, Ota K, Garruto RM. Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia. Neurotoxicology. 1993;14:445-450.
204. Imon Y, Yamaguchi S, Yamamura Y, et al. Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases. J Neurol Sci. 1995;134(suppl):27-32.
205. Leveugle B, Spik G, Perl DP, et al. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res. 1994;650:20-31.
206. Gaudette M, Hirano M, Siddique T. Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:83-89.
207. Danzeisen R, Achsel T, Bederke U, et al. Superoxide dismutase 1 modulates expression of transferrin receptor. J Biol Inorg Chem. 2006;11:489-498.
208. Wang XS, Lee S, Simmons Z, et al. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci. 2004;227:27-33.
209. Goodall EF, Greenway MJ, van Marion I, et al. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology. 2005;65:934-937.
210. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 2001;18:685-716.
211. Connor JR, Menzies SL, St Martin SM, et al. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res. 1992;31:75-83.
212. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci. 1996;143:137-142.
213. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology. 1998;19:339-345.
214. Bartzokis G, Sultzer D, Cummings J, et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry. 2000;57:47-53.
215. LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res. 1997;760:298-303.
216. Smith MA, Richey Harris PL, Sayre LM, et al. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997;17:2653-2657.
217. Sayre LM, Zelasko DA, Harris PL, et al. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem. 1997;68:2092-2097.
218. Sayre LM, Perry G, Harris PL, et al. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem. 2000;74:270-279.
219. Collingwood JF, Mikhaylova A, Davidson M, et al. In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. J Alzheimers Dis. 2005;7:267-272.
220. Garzon-Rodriguez W, Yatsimirsky AK, Glabe CG. Binding of Zn(II), Cu(II), and Fe(II) ions to Alzheimer's A beta peptide studied by fluorescence. Bioorg Med Chem Lett. 1999;9:2243-2248.
221. Mantyh PW, Ghilardi JR, Rogers S, et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem. 1993;61:1171-1174.
222. Rottkamp CA, Raina AK, Zhu X, et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med. 2001;30:447-450.
223. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002;277:45518-45528.
224. Bodovitz S, Falduto MT, Frail DE, et al. Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. J Neurochem. 1995;64:307-315.
225. Honda K, Casadesus G, Petersen RB, et al. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci. 2004;1012:179-182.
226. Quintana C, Bellefqih S, Laval JY, et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol. 2006;153:42-54.
227. Connor JR, Snyder BS, Beard JL, et al. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res. 1992;31:327-335.
228. Smith MA, Wehr K, Harris PL, et al. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res. 1998;788:232-236.
229. Jefferies WA, Food MR, Gabathuler R, et al. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res. 1996;712:122-126.
230. Castellani RJ, Smith MA, Nunomura A, et al. Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med. 1999;26:1508-1512.
231. Kim DK, Seo MY, Lim SW, et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology. 2001;25:84-90.
232. Sampietro M, Caputo L, Casatta A, et al. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging. 2001;22:563-568.
233. Pulliam JF, Jennings CD, Kryscio RJ, et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet. 2003;119:48-53.
234. Gassen M, Glinka Y, Pinchasi B, et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol. 1996;308:219-225.
235. Mandel SA, Avramovich-Tirosh Y, Reznichenko L, et al. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals. 2005;14:46-60.
236. Mandel S, Weinreb O, Amit T, et al. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3- gallate: implications for neurodegenerative diseases. J Neurochem. 2004;88:1555-1569.
237. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 2003;37:899-909.
238. Salamone JD, Zigmond MJ, Stricker EM. Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions. Neuroscience. 1990;39:17-24.
239. Zigmond MJ, Stricker EM. Supersensitivity after intraventricular 6-hydroxydopamine: relation to dopamine depletion. Experientia. 1980;36:436-438.
240. Ben-Shachar D, Eshel G, Finberg JP, et al. The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem. 1991;56:1441-1444.
241. Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004;1012:306-325.
242. Weinreb O, Mandel S, Youdim MB. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J. 2003;17:935-937.
243. Glinka YY, Youdim MB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol. 1995;292:329-332.
244. Glinka Y, Tipton KF, Youdim MB. Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur J Pharmacol. 1998;351:121-129.
245. Glinka Y, Tipton KF, Youdim MB. Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J Neurochem. 1996;66:2004-2010.
246. Shachar DB, Kahana N, Kampel V, et al. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology. 2004;46:254-263.
247. Grunblatt E, Mandel S, Maor G, et al. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem. 2001;78:1-12.
248. Grunblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm. 2004;111:1543-1573.
249. Gal S, Zheng H, Fridkin M, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem. 2005;95:79-88.
250. Zheng H, Gal S, Weiner LM, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem. 2005;95:68-78.
251. Zheng H, Weiner LM, Bar-Am O, et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem. 2005;13:773-783.
252. Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5:863-873.